“Breakthrough technologies deserve a breakthrough in the way the FDA evaluates them.” – Andrew Von Eschenbach
Mr. Von Eschenbach couldn’t have stated it any clearer. On February 14, the Wall Street Journal posted an on-line article by Mr. Eschenbach titled:
Medical Innovation: How the U.S. Can Retain Its Lead, The FDA should approve drugs based on safety and leave efficacy testing for post-market studies.
Mr. Eschenbach, former Director of NCI at the Food and Drug Administration discussed the need for changes at the FDA and offered his insight as to how Congress can help make those changes a reality.